Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an ...

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine ...

Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an ...

An artificial intelligence (AI)-based model accurately classified pediatric sarcomas using digital pathology images alone, ...

Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different ...

Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2 ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

A woman said she was inspired to run her first marathon by her dad's rare cancer diagnosis. Zoë Driver, who lives in Wylye ...

Daraine Cunningham’s swollen eye was reportedly dismissed for years, but after finally getting surgery, a life-changing ...

Family and friends of a Salisbury woman who died from a rare form of cancer just six days after her 25th birthday are taking ...